Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 8/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303355 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL13401664 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL3298142 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL12079329 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL12087889 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL13896357 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL1660605 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL12878693 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL12091626 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 | |
| SCHEMBL30578655 | 1.00 | PYGB (0.51) | PYGBGAACA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1842527-B1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | OREAL (FR) | 2019-06-26 | — | — | EP | claimed |
| US-20070265210-A1 | Administration of C-glycoside compounds for protecting and/or activating gammadeltaT lymphocytes | L'OREAL (FR) | 2007-11-15 | — | — | US | claimed |
| US-20070248556-A1 | Administration of C-glycoside compounds for activating and regulating cutaneous immunity | L'OREAL (FR) | 2007-10-25 | — | — | US | claimed |
| EP-1844757-A1 | Use of c-glycoside derivatives as an agent for protecting and/or activating gamma/delta t lymphocytes | L'Oréal (FR) | 2007-10-17 | — | — | EP | claimed |
| EP-1842527-A1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | L'Oréal (FR) | 2007-10-10 | — | — | EP | claimed |
| US-11760708-B2 | Compositions and methods for reducing enones to saturated alcohols or ketones | YALE UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760708-B2 | Compositions and methods for reducing enones to saturated alcohols or ketones | YALE UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11192913-B2 | C-glycoside amine derivatives and methods of making | The United States of America, as represented The Secretary of Agriculture (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210214383-A1 | C-GLYCOSIDE AMINE DERIVATIVES AND METHODS OF MAKING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2021-07-15 | — | — | US | disclosed |
| US-20210163384-A1 | Compositions and Methods for Reducing Enones to Saturated Alcohols | YALE UNIVERSITY | 2021-06-03 | — | — | US | disclosed |
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| WO-2019182087-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-09-26 | — | — | WO | disclosed |
| EP-1842527-A1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | L'Oréal (FR) | 2007-10-10 | — | — | EP | disclosed |
| EP-1842527-A1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | L'Oréal (FR) | 2007-10-10 | — | — | EP | disclosed |
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL S.A. (FR) | 2006-10-05 | — | — | US | disclosed |
| US-7049300-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL (FR) | 2006-05-23 | — | — | US | disclosed |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | SOCIETE L'OREAL S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345919-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051803-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051828-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163384-A1 | Compositions and Methods for Reducing Enones to Saturated Alcohols | ADH1C, ADH1A, GK | PYGB 3866/4885GAA 2427/4885CA12 2940/4885 |
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | PYGB 1844/4885GAA 106/4885CA12 372/4885 |
| US-20070265210-A1 | Administration of C-glycoside compounds for protecting and/or activating gammadeltaT lymphocytes | NFATC1, EBP, CD4 | PYGB 286/4885GAA 382/4885CA12 652/4885 |
| US-20070248556-A1 | Administration of C-glycoside compounds for activating and regulating cutaneous immunity | NFATC1, CCL11, CCR7 | PYGB 2778/4885GAA 395/4885CA12 1084/4885 |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | PYGB 1844/4885GAA 106/4885CA12 372/4885 |
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OSTC, FUT6, FUT5 | PYGB 1014/4885GAA 94/4885CA12 155/4885 |
| US-11760708-B2 | Compositions and methods for reducing enones to saturated alcohols or ketones | ADH1C, ADH1A, GK | PYGB 3486/4885GAA 2370/4885CA12 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.